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Abstract
Background Clinicians are required to assimilate, critically
evaluate, and extrapolate information to support appropri-
ate use of biosimilars across indications.
Objectives The objective of this study was to systemati-
cally collate all published data in order to assess the weight
(quantity and quality) of available evidence for each
molecule and inform and support healthcare decision-
making in chronic inflammatory diseases.
Methods MEDLINE, EMBASE, and ISI Web of
Science were searched to September 2015. Selected con-
ference proceedings were searched from 2012 to July 2015.
Studies disclosing biosimilars with unique identifiers were
categorized by originator, study type, and indication. Risk of
bias assessments were performed. Intended copies were
differentiated as commercially available agents without
evidence of rigorous comparative biosimilarity evaluations.
Results Proposed biosimilars for adalimumab, etanercept,
infliximab, and rituximab are reported in the published lit-
erature. Across indications, approved biosimilars infliximab
CT-P13, SB2, and etanercept SB4 have published studies
involving the largest number of patients or healthy subjects
(n = 1405, 743, and 734, respectively), mostly in rheuma-
toid arthritis. At data cut-off, only CT-P13 had published
data in ankylosing spondylitis (n = 250; randomized control
trial) and ulcerative colitis/Crohn’s disease (n = 336;
observational studies). Published data were not available for
ongoing studies in psoriasis patients. Four intended copies
were identified in published studies (total: n = 1430;
n = 1372 in observational studies). Thematic analysis of
non-empirical publications showed that indication extrapo-
lation remains an issue, particularly for gastroenterologists.
Conclusions While most agents display a moderate to high
degree of similarity to their originator in the published
studies identified, large discrepancies persist in the overall
amount and type of data available in the public domain.
Significant gaps exist particularly for intended copies,
reinforcing the need to maintain a clear differentiation
between these molecules and true biosimilars.
Key Points
There is a significant body of evidence in the
published literature to support infliximab biosimilars
CT-P13, SB2, and etanercept biosimilar SB4 for
rheumatoid arthritis, but knowledge gaps still exist
both in the amount and type of data available. These
gaps are more pronounced for other molecules across
chronic inflammatory diseases, and most pronounced
for intended copies.
Rheumatoid arthritis is the first indication for which
biosimilars have been launched and experience here
will influence how the broader sector evolves.
Ongoing dissemination of data by all manufacturers
is imperative to support adoption of biosimilars.
Leah Isakov was an employee of Pfizer at the time the study was
conducted.
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A biosimilar or follow-on biologic [1] is a biologic
medicinal product that contains a version of the active
substance of an already authorized original biologic
medicinal product [2–4]. Over 700 biosimilar products are
reported to be in preclinical and clinical trials [5]. For
biosimilar drug approval, data must be generated to
establish whether a biosimilar can safely and effectively be
used instead of the originator product.
Although highly efficacious, biologic therapy for chronic
inflammatory disease is expensive [6]. The expectation
among patients, treating physicians, and healthcare provi-
ders is that biosimilars should be highly similar in efficacy,
comparable in safety, including immunogenicity, but lower
in price than their reference products [7]. The introduction of
biosimilars can help expand access to safe and effective
treatment options for clinicians and patients [6].
Several biosimilars are now available for the treatment
of chronic inflammatory diseases. CT-P13 (Remsima/In-
flectra, an infliximab biosimilar) was the first EU-ap-
proved monoclonal antibody (mAb) biosimilar, obtaining
market authorization in September 2013 for all approved
indications of the innovator drug, including rheumatoid
arthritis (RA), ankylosing spondylitis (AS), psoriatic
arthritis (PsA), psoriasis, Crohn’s disease (CD), and
ulcerative colitis (UC). In 2014, Health Canada initially
approved CT-P13 for all approved indications of infliximab
except for UC and CD [8]; Health Canada subsequently
approved CT-P13 for additional indications, including CD,
fistulizing CD, and UC [9].The addition of CD, fistulizing
CD, and UC to the approved indications was granted on the
basis of similarity between CT-P13 and the reference
product Remicade in product quality, mechanism of
action, disease pathophysiology, safety profile, dosage
regimen, and on clinical experience with the reference
product [9]. In February 2016, the US Food and Drug
Administration (FDA) Arthritis Advisory Committee
approved CT-P13 for all indications of the reference pro-
duct, making it the first biosimilar mAb therapy to be
reviewed by the FDA for licensure in the USA.
In November 2015, the European Medicines Agency
(EMA) recommended marketing approval for SB4
(Benepali, an etanercept biosimilar) for the treatment of
RA, AS, PsA, and psoriasis [7]. On 1 June 2016, the EMA
Committee for Medicinal Products for Human Use
announced a positive opinion on SB2 (Flixabi, an inflix-
imab biosimilar) for the treatment of RA, CD, UC, AS,
PsA, and psoriasis [10]. On 12 July 2016, the FDA advi-
sory panel voted in favor of recommending approval for
ABP 501, Amgen’s proposed biosimilar of adalimumab, to
treat seven chronic inflammatory diseases, including RA,
PsA, CD, UC, and plaque psoriasis [11]. Finally, on
13 July 2016, the FDA Arthritis Advisory Committee
unanimously voted to recommend approval of Sandoz’s
GP2015 (an etanercept biosimilar) as the totality of the
evidence demonstrated that GP2015 is similar to US-li-
censed Enbrel (etanercept) [12].
Similarity to the reference product in terms of quality
characteristics, biologic activity, efficacy, and safety must
be established before biosimilar products can be marketed
in the USA, Europe, or other regulated countries [2].
Numerous batches of the innovator reference product are
routinely tested to establish the characteristic range. Man-
ufacturers must provide high-quality evidence of similar
efficacy and safety outcomes, including a comprehensive
immunogenicity assessment to satisfy the stringent
requirements for EMA and FDA approval.
In contrast, ‘intended copies’ are copies of originator bio-
logics that have not undergone rigorous comparative evalua-
tions as recommended by the leading regulatory authorities,
but are nevertheless being sold in some countries. There is a
lack of information about the efficacy and safety of intended
copies compared with the originator. Furthermore, they may
have clinically noticeable differences in quality characteris-
tics, pharmacokinetics, efficacy, or safety. The extent and
quality of available data between proposed biosimilars and
intended copies often greatly differ [13].
A comprehensive systematic literature review (SLR)
was recently undertaken to identify, collate, and summarize
all published empirical evidence on named biosimilars and
intended copies of originator mAbs and fusion proteins
(Jacobs et al. [14]; see page 489 of this issue). The original
analysis aimed to summarize the range of available data
and number and diversity of publications describing
biosimilars (for the treatment of chronic inflammatory
disease along with other disease areas, including oncol-
ogy). Here, we explore in greater depth the findings for
biosimilars indicated for chronic inflammatory disease.
2 Methods
2.1 Systematic Literature Review
A detailed description of the methods used in this SLR can
be found in Jacobs et al. [14] (see page 489 of this issue).
First, the search strategy captured mAb and fusion protein
terms; then included the different terminologies for
biosimilar products, such as biosimilars, subsequent entry
biologics, follow-on biologics, follow-on proteins, bio-
comparables, biogenerics, similar biotherapeutic products,
or intended copies and biobetters (which were analyzed
separately). Publications were required to contain both
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‘‘mAb/fusion protein’’ and ‘‘biosimilar’’ terms. Here we
report the results of biosimilars indicated for the treatment
of RA (active, moderate, severe), psoriasis or plaque pso-
riasis, PsA, AS, CD, UC, scleroderma, and dermato-
myositis. The search results were filtered using the study
designs of interest and controlled vocabulary and free-text
terms were applied.
MEDLINE/MEDLINE In-Process and EMBASE
(searched using the OVIDSP interface), and ISI Web of
Science were searched from database inception to
3 September 2015. The search was carried out on 27 April
2015 and repeated on 3 September 2015 to capture the
latest full-text publications. In addition to the publication
search and in order to identify recent studies not yet pub-
lished as full-text articles and/or to provide additional data
from previously published studies, a hand search of rele-
vant conference proceedings (17 conferences) was con-
ducted between 1 January 2012 and 31 July 2015
(Electronic Supplementary Material [ESM] Table S1).
The search result was limited to references published in
the English language. For this analysis, biosimilars are
differentiated from intended copies based on meeting the
rigorous regulatory requirements for biosimilarity, as
described by major regulatory health authorities such as the
EMA, FDA, the World Health Organization (WHO),
Health Canada, the Pharmaceuticals Medical Devices
Agency/Japan Ministry for Health Labour and Welfare
(PMDA/MHLW), or the Korean Ministry of Food and
Drug Safety (MFDS) in the Republic of Korea [15, 16].
Guidelines for biosimilar approval have also been issued
by Administracio´n Nacional de Medicamentos, Alimentos
y Tecnologı´a Me´dica (ANMAT) in Argentina, Ageˆncia
Nacional de Vigilaˆncia Sanita´ria (ANVISA) in Brazil, and
Comisio´n Federal para la Proteccio´n contra Riesgos Sani-
tario (COFEPRIS) in Mexico. However, it should be noted
that products approved in Latin American countries might
not have been authorized following as strict a regulatory
process as is required for approval of biosimilars in the
USA or EU [17]. The biosimilar approval pathway was
recently updated by India’s Central Drugs Standard Control
Organization (CDSCO) [18]. Other markets have issued
guidance on biosimilars, although evaluation of the
biosimilar approval pathways by regulatory authorities
outside of the major markets was considered beyond the
scope of this review.
Results from the SLR were split further into two com-
ponents: the empirical analysis, which focused on peer-
reviewed publications of clinical, pharmacovigilance, and
observational empirical data, and the non-empirical anal-
ysis, which included opinion pieces or commentaries,
publications describing product-related patient support
programs, and articles on manufacturing and supply issues.
Non-empirical articles were further classified into general
thematic categories to summarize key topics being dis-
cussed in the field of biosimilar medicines. Empirical
studies were also categorized by type: preclinical (includ-
ing analytical, functional, or nonclinical studies), clinical
(pharmacokinetic/safety trials and preliminary or compar-
ative safety/efficacy trials), or observational (prospective,
retrospective, and post-marketing) studies. Results of
clinical trial searches (from ClinicalTrials.gov) were also
included as a separate subsection, and planned or ongoing
clinical trials of biosimilars, where results were yet to be
published, were explored.
2.2 Risk of Bias (Quality) Assessment
In accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines, a validated tool matched to the study type was
used to assess the strength/validity of the empirical data for
each individual study [19, 20]. In cases where multiple
publications were retrieved for the same study, quality
assessments were only conducted on the first original
publication or first full-text publication. Further informa-
tion on each tool is provided in the ESM.
The assessment of the quality of randomized controlled
trials (RCTs) was carried out using recommendations from
the National Institute for Health and Care Excellence
(NICE) single technology appraisal (STA) manufacturer’s
template [21] and the Jadad scoring system [22] (ESM
Table S2, ESM Fig. S1).
The Downs and Black [23] instrument was used to
assess the quality of all non-randomized studies. As studies
published as abstracts in conference proceedings have
limited information, the Downs and Black instrument was
modified to include only the most relevant qualifying
parameters (n = 12 of 26) for quality assessment, as listed
in ESM Tables S3 and S4. Pharmacoeconomic studies were
evaluated using Drummond’s checklist for assessing eco-
nomic evaluations [24]. Animal studies were assessed
using SYRCLE’s (SYstematic Review Centre for Labora-
tory animal Experimentation) risk of bias tool [25]. Con-
ference abstracts of analytical/nonclinical and economic
studies were not evaluated, as suitable tools were not
available at the time of analysis. Full-text analytical and
cell-based studies were also not evaluated for the same
reason.
3 Results
3.1 Literature and Conference Search
The literature search returned 1,991 publications that were
identified through title and abstract screening, and those
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relevant to the topic of biosimilars were retained (768
publications in total). Of the included references, 301
(39%) addressed biosimilars for the treatment of chronic
inflammatory conditions. The numbers of publications
included in the analysis are presented in a PRISMA flow
diagram (shown in ESM Fig. S2). Of note, in cases where
encore (or duplicate) publications were retrieved for stud-
ies, the information was compared with the original (first
published article) and excluded if no additional data were
provided. If new data were identified, encore publications
were included along with the original publication. This
would be reflected in the overall publication count but not
in the overall study count. Named biosimilars (i.e., where a
unique identifier was provided) were identified in 55
studies (96 publications) in chronic inflammatory disease
(Fig. 1).
3.2 Preclinical and Pharmacokinetic/Safety Data
in Healthy Subjects
3.2.1 Adalimumab Biosimilars
Studies of adalimumab biosimilars are presented in
Table 1.
ABP 501 (Amgen) Pharmacokinetic/safety studies for
ABP 501 have been reported [28, 26, 27]. In healthy sub-
jects, ABP 501 was reported to demonstrate pharmacoki-
netic equivalence to adalimumab and, overall, no safety or
immunogenicity concerns were raised. The combined
results of analytical and nonclinical in vitro studies suggest
a high degree of similarity between ABP 501 and adali-
mumab, despite some variations reported in structural
composition.
ExemptiaTM (Cadila Healthcare) Bandyopadhyay and
coworkers [40] reported on the physicochemical properties
and in vivo pharmacokinetic and toxicology profile of
ExemptiaTM in the journal Biosimilars and concluded that
the molecule displayed highly similar characteristics to
adalimumab. It should be noted that studies from non-in-
dexed publications were not included in this review, and
therefore the data from this publication were not extracted.
Based on the information from this study and other infor-
mation which came to the attention of the authors, it seems
reasonable to assume that this molecule may be considered
a biosimilar and not an intended copy; however, compli-
ance with the EMA, FDA, and WHO requirements is not
yet fully transparent.
GP2017 (Sandoz) A published nonclinical study found
GP2017 to be well-tolerated among tested species (mouse,
rabbit, and monkey), and that it displayed a similar phar-
macokinetic profile to that of adalimumab [37, 36, 35].
PF-06410293 (Pfizer) Analytical/nonclinical studies
reporting results of peptide mapping experiments
comparing PF-06410293 and adalimumab revealed highly
similar primary sequence structures [38].
SB5 (Samsung Bioepis) SB5 has been studied in phar-
macokinetic/safety studies in healthy volunteers to estab-
lish bioequivalence with adalimumab [41]. The
pharmacokinetic data were not reported, but all parameters
were found to fall within the required range for equiva-
lence. The majority of adverse events (AEs) were mild in
severity and comparable to the extent observed in adali-
mumab-treated healthy subjects.
3.2.2 Etanercept Biosimilars
Studies of etanercept biosimilars are presented in Table 2.
ENIA11 (TuNEX; Mycenax Biotech/TSH Biopharm
Corp) One pharmacokinetic/safety RCT was identified for
ENIA11, wherein 23 healthy male subjects were random-
ized to study medication and reported similar pharma-
cokinetic/pharmacodynamic outcomes, with no serious
AEs compared with etanercept [43, 42].
HD203 (DavictrelTM; Hanwha Chemical) In a double-
blind RCT comparing HD203 with etanercept in healthy
subjects, pharmacokinetic/pharmacodynamic outcomes
were similar between the two drugs and no serious AEs
were observed [44].
LBEC0101 (LG Life Sciences) One pharmacokinetic/
safety RCT for LBEC0101 in healthy volunteers was
found. It reported similar pharmacokinetic/pharmacody-
namic outcomes between this biosimilar and etanercept
[47].
SB4 (Benepali; Samsung Bioepis) In a pharmacoki-
netic/safety trial, pharmacokinetic equivalence was repor-
ted and SB4 was well-tolerated in healthy male subjects
with a similar safety profile to etanercept [48, 49].
AVG01 (AventTM; Avesthagen) One analytical/nonclin-
ical study reported that AVG01 was highly similar to
etanercept [52].
GP2015 (Sandoz) Two nonclinical studies were identi-
fied for GP2015. Both reported that GP2015 was highly
similar to etanercept with regard to target binding, anti-
tumor necrosis factor (TNF)-a biologic activity, and
pharmacokinetic exposure [51, 53].
3.2.3 Infliximab Biosimilars
Studies of infliximab biosimilars are presented in Table 3.
BOW015 (Infimab; Ranbaxy Laboratories) A recent
announcement from Ranbaxy Laboratories indicates that
BOW015 has been discontinued. Prior to this, the phar-
macokinetic, safety, and immunogenicity profiles of
BOW015 and infliximab were compared in healthy vol-
unteers [54, 55]. Studied pharmacokinetic parameters and
safety outcomes were reported to be comparable between
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the biosimilar and the originator. Within the SLR time-
frame, no analytical or nonclinical data had been published
or reported for BOW015 to validate its structural and
functional biosimilarity to infliximab.
PF-06438179 (Pfizer) The pharmacokinetics and
safety attributes of PF-06438179 have been evaluated in
healthy volunteers [94, 95, 93, 98, 99, 97, 96]. Reports
of studies confirmed pharmacokinetic bioequivalence of
PF-06438179 as compared with infliximab, with similar
incidences of AEs and lower occurrence of immuno-
genicity in PF-06438179 versus infliximab-treated sub-
jects. The biochemical characteristics and in vitro/
in vivo biologic activity of PF-06438179 have been
studied and reported. The data suggest that PF-06438179
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Fig. 1 Frequency of publications of reported named biosimilars in
chronic inflammatory diseases. Note: publications were classified into
the most relevant category, which in some cases was more than one.
Therefore, the number of publications classified into each therapeutic
area category does not sum to the total number of publications. For
example, overlap in licensed indications for originators/biosimilars
led to multiple categorization. Among the empirical references,
several (seven) include both nonclinical and human data, and as such
have been classified into both categories. IC Intended copy, RCT
randomized controlled trial
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SB2 (Flixabi; Samsung Bioepis) The pharmacokinet-
ics, safety, and immunogenicity profiles were reportedly
similar between SB2 and infliximab in healthy volunteers
[41]. No analytical or nonclinical studies comparing
structural or functional similarity of SB2 versus infliximab
had been published at the time of review.
CT-P13 (Remsima/Inflectra; Celltrion) CT-P13 was
evaluated in healthy human volunteers and demonstrated
similar safety and pharmacokinetic profiles as those for
infliximab [63]. The physicochemical properties of CT-P13
were also characterized using combined analytical tech-
niques [91, 90]. The results, overall, demonstrated that CT-
P13 has comparable structural properties to that of inflix-
imab. A nonclinical cell-based study has also been repor-
ted, confirming bioequivalence in vitro.
3.2.4 Rituximab Biosimilars
Studies of rituximab biosimilars are presented in Table 4.
GP2013 (Sandoz) The functional similarity and pharma-
cokinetic properties of GP2013 compared with rituximab
have been assessed both in vitro (using lymphoma cell lines)
[117] and in vivo (mouse xenograft models and cynomolgus
monkeys) [117, 115]. The studies also included structural
comparability assessments using a combination of bio-
chemical techniques. These studies suggest high levels of
similarity between GP2013 and the originator rituximab.
PF-05280586 (Pfizer) Comparative nonclinical studies
have been published for PF-05280586 and rituximab, based
on in vitro functional assessments and evaluation of safety or
pharmacokinetic in vivo (monkeys) [114, 109, 111, 113, 108,
112]. In vitro data (complement-dependent cytotoxicity
assays and biologic activity) provide evidence of functional
similarity to the originator. The safety, tolerability, and
pharmacokinetic/pharmacodynamic profile of PF-05280586
in monkeys is reported to be comparable to rituximab. These
studies also included comprehensive analytical assessments
of the primary and higher-order structure, and concluded high
similarity between the biosimilar and the originator.
RTXM83 (Mabxience) The biological potency and
pharmacokinetic/pharmacodynamic properties of RTXM83
have been evaluated in a single preclinical study (unspec-
ified cell line or cynomolgus monkeys) [118]. The results
of the study suggest functional similarity and analogous
pharmacokinetic/pharmacodynamic properties between the
biosimilar and originator.
3.3 Clinical Evidence in Rheumatoid Arthritis (RA)
3.3.1 Adalimumab Biosimilars in RA
Studies of adalimumab biosimilars are presented in
Table 1.
ExemptiaTM (Cadila Healthcare) The safety and efficacy
of ExemptiaTM versus adalimumab have been reported in a
comparative safety/efficacy trial in patients (n = 120) with
moderate-to-severe RA [33]. The results demonstrated no
significant difference in any of the parameters (with respect
to efficacy, tolerability, and safety) at the end of the study
between the two treatment groups. No analytical or non-
clinical study data evaluating the structural composition or
functional similarity of ExemptiaTM with respect to adali-
mumab were extracted during this literature review.
3.3.2 Etanercept Biosimilars in RA
Studies of etanercept biosimilars are presented in Table 2.
HD203 (DavictrelTM; Hanwha Chemical) In a compar-
ative safety/efficacy trial comparing HD203 with etaner-
cept in patients with active RA (n = 233) and insufficient
response to methotrexate, the proportion of patients
achieving American College of Rheumatology (ACR)
improvement of 20% (ACR20) at week 24 was not sig-
nificantly different between HD203 and etanercept. Similar
trends were seen for ACR improvement of 50% (ACR50)
and of 70% (ACR70) [46, 45].
SB4 (Benepali; Samsung Bioepis) One comparative
safety/efficacy RCT for SB4 was found for patients with
RA (n = 596), which reported that SB4 was equivalent to
etanercept in terms of efficacy and had a comparable safety
profile [48, 49].
3.3.3 Infliximab Biosimilars in RA
Studies of infliximab biosimilars are presented in Table 3.
BOW015 (Infimab; Ranbaxy Laboratories) Prior to
discontinuation, BOW015 was investigated in a compara-
tive safety/efficacy equivalence study in patients with RA
(n = 189). Results of the study implied similarity with
respect to efficacy (disease activity and physical function)
and safety compared with infliximab [54, 119, 57, 56, 120].
SB2 (Flixabi; Samsung Bioepis) SB2 has been studied
in a comparative safety/efficacy study to demonstrate
equivalence of efficacy, safety, immunogenicity, and
pharmacokinetic outcomes versus infliximab in patients
with moderate to severe RA (n = 584) [100, 101]. SB2
demonstrated equivalent efficacy to infliximab in regards to
ACR20 response. The pharmacokinetic, safety, and
immunogenicity profiles were also reportedly similar to
infliximab.
CT-P13 (Remsima/Inflectra; Celltrion) In the PLA-
NETRA (Programme evaLuating the Autoimmune disease
iNvEstigational drug cT-p13 in RA patients) comparative
safety/efficacy study, CT-P13 displayed equivalent efficacy
to infliximab, was well-tolerated, and had a comparable
pharmacokinetic, safety, and immunogenicity profile, as
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Table 4 Outcomes for rituximab biosimilars
Study type [patients
(n)]










ACR20 (%) 63.0 66.7
ACR50 (%) 37.0 31.3
ACR70 (%) 16.0 14.6
Safety, week 24:
All AEs (n)
Treatment AEs 166 88















ADAb (%) 17.6 17.6
PK/PD, week 24:




7870.8 8010.4 Ratio: 0.983
(0.896–1.078)b
AUC of B cell
count (cells/lL)







CA [104]; CA [105];









CRP (mg/L) Improved Improved
Safety, week 16:
Serious AEs (n) 5 6
PK/PD, week 16:




























SYRCLE’S risk of bias:
moderate; unclear = 9,
low risk = 13CDC Similar Similar
Safety (monkey): Similar Similar

































Cmax, 2 mg/kg [lg/mL (SD)] 74.0 (15.5) 80.3 (7.95)




















t, 2 mg/kg [h (SD)] 1.22 (2.37) 0.08 (0.0)
t, 10 mg/kg [h (SD)] 0.24 (0.37) 0.24 (0.37)
t, 20 mg/kg [h (SD)] 0.24 (0.37) 0.39 (0.47)
t, repeated-dose [h (SD)] 0.70 (1.57) 0.35 (0.43)
t, repeated-dose [h (SD)] 0.48 (0.47) 0.67 (0.46)
tmax Similar Similar




CD3–CD20?, 2 mg; 10 mg;




CD3–CD20?, 2 mg; 10 mg;




CD3–CD20?, 2 mg; 10 mg;
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Table 4 continued





10 mg; 20 mg, day 4 (%)
86.3; 90.2; 90.5 83.5; 85.2; 87.1
CD3–CD19?, 2 mg;
10 mg; 20 mg, day 15 (%)
81.0; 85.6; 91.1 74.6; 88.7; 83.1
CD3–CD19?, 2 mg;
10 mg; 20mg, day 92 (%)
9.8; 2.1; 29.6 6.2; –5.2; –8.4
CD3–CD40?, 22 mg;
10 mg; 20 mg, day 4 (%)
85.9; 91.4; 92.6 88.0; 87.3; 88.3
CD3–CD40?, 2 mg;
10 mg; 20 mg, day 15 (%)
81.0; 84.8; 94.9 78.4; 88.2; 88.0
CD3–CD40?, 2 mg;
10 mg; 20 mg, day 92 (%)
25.3; 1.5; 18.7 25.5; –30.0; 5.3
Repeated-dose:
CD3–CD20?, 2 mg;
10 mg; 20 mg, day 4 (%)
100 100
CD3–CD20?, 2 mg;
10 mg; 20 mg, day 15 (%)
99.9 99.7
CD3–CD20?, 2 mg;
















10 mg; 20 mg, day 4 (%)
96.1 92.1
CD3–CD19?, 2 mg;
10 mg; 20 mg, day 15 (%)
90.3 89.6 –
CD3–CD19?, 2 mg;




10 mg; 20 mg, day 4 (%)
97.3 86.0 –
CD3–CD40?, 2 mg;
10 mg; 20 mg, day 15 (%)
97.3 96.8
CD3–CD40?, 2 mg;
10 mg; 20 mg, day 121
(%)
74.3 77.1
Nonclinical (cell-based) CA [111] Functional assessment
(in vitro):
Not evaluatedd
Biologic activity (%) 93–114 USA/EU: 79–135






CDC dose-response curve Superimposable Superimposable
Binding to FccRIIIa Similar Similar
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Table 4 continued












Composition: SYRCLE’S risk of
bias: moderate;
unclear = 9, low
risk = 13
Tryptic peptide mapping Superimposable Superimposable
Analytical/nonclinical
(cell-based)




Glycan quantification Similar Similar
Purity NR NR












CA [112] Composition: Not evaluatedd













10 = low risk
ADCC Overlapping Overlapping NS


















ADAb (days) [9 [9
PK/PD (monkey):
AUC (%) 0.80–1.25 0.80–1.25
Cmax 13% lower 13% higher
CD20 levels (%) 80–125 80–125
Composition: Similar Similar
Glycan quantification NR NR




Size heterogeneity NR NR





97–108 96–100 p\ 0.0001
ADCC (%) 86–105 70–132 p\ 0.0001
CDC (%) 99–111 95–127 p\ 0.0001
Apoptosis (%) 88–99 88–102 p\ 0.0001
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compared with infliximab in patients with RA (n = 606)
[66, 121, 67, 72, 69, 102, 71]. An observational cross-
sectional study, which included RA patients from Romania
who were treated with biologic agents, assessed efficacy
and safety data after 2 years of treatment with infliximab,
CT-P13, etanercept, adalimumab, or rituximab [122].
Table 4 continued









Composition: Similar Similar SYRCLE’s risk of
bias: moderate;
12 = unclear,
10 = low risk
Glycan quantification NR NR




Size heterogeneity NR NR
Analytical/nonclinical
(cell-based)
[117] Composition: Not evaluatedd
Primary structure Identical Identical
Higher order structure Expected
pattern
Stability Superimposable














CA [118] Functional assessment
(in vitro):
Not evaluatedd
ADCC, binding Similar Similar










CA [118] Composition: Not evaluatedd




Abs antibodies, ACR20, 50, 70 American College of Rheumatology 20, 50, 70% improvement criteria, ADAb anti-drug antibodies, ADCC
antibody-dependent cell-mediated cytotoxicity, AE adverse event, AUC area under the plasma concentration–time curve, CA conference abstract,
CDC complement-dependent cytotoxicity, Cmax maximum concentration, CRP C-reactive protein, D&B Downs and Black (tool), DAS28 Disease
Activity Score in 28 joints, FccRIIIa Fc gamma receptor IIIa, NR not reported, NS not significant, PD pharmacodynamic, PK pharmacokinetic,
RA rheumatoid arthritis, RCT randomized controlled trial, RTX rituximab, SD standard deviation, SU-DHL Southwestern University Diffuse
Histiocytic Lymphoma, SYRCLE SYstematic Review Centre for Laboratory animal Experimentation, t half-life, tmax time to maximum
concentration, ?ve positive, –ve negative
a Qualitative data for biosimilarity as stated by the corresponding study authors
b 90% confidence intervals shown in parentheses
c 95% confidence intervals shown in parentheses
d Quality assessment not conducted due to the absence of validated tools specific for the study type, at the time of analysis
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3.3.4 Rituximab Biosimilars in RA
Studies of rituximab biosimilars are presented in Table 4.
CT-P10 (Celltrion) CT-P10 was evaluated in a phar-
macokinetic/safety trial in patients with active RA and an
inadequate response or intolerance to prior anti-TNF agents
(n = 154) [102, 103]. The published findings of the study
concluded equivalence in terms of efficacy, safety, and
pharmacokinetic/pharmacodynamic outcomes compared
with rituximab. There was some indication, however, that
antidrug antibodies-positive patients in the rituximab group
may have been at greater risk of serious AEs than those in
the CT-P10 group.
PF-05280586 (Pfizer) Data from a pharmacokinetic/
safety study on PF-05280586 in patients with active RA on
methotrexate and with prior inadequate response to anti-
TNF therapies (n = 220) also inferred equivalence of
efficacy, safety, and pharmacokinetic/pharmacodynamic
performance compared with rituximab.
3.4 Clinical Evidence in Ankylosing Spondylitis
(AS)
3.4.1 Infliximab Biosimilars in AS
Studies of infliximab biosimilars are presented in Table 3.
CT-P13 (Remsima/Inflectra; Celltrion) CT-P13 has
been evaluated in a pharmacokinetic/safety study (PLA-
NETAS) study [63, 59, 58, 61, 123, 62]. The pharma-
cokinetic profiles of CT-P13 and infliximab were
equivalent in patients with active AS (n = 250). CT-P13
was well-tolerated, with an efficacy and safety profile
comparable with that of infliximab over the duration of the
study.
3.5 Clinical Evidence in Ulcerative Colitis (UC)
and Crohn’s Disease (CD)
3.5.1 Infliximab Biosimilars in UC/CD
Studies of infliximab biosimilars are presented in Table 3.
CT-P13 (Remsima/Inflectra; Celltrion) Several
observational (post-marketing) studies have been reported
for CT-P13 that investigated the efficacy and impact of
switching from the biologic originator to CT-P13 in
patients with UC or CD (n = 336)
[80, 81, 76, 77, 78, 74, 79, 75, 82]. In one study of 110
patients with CD or UC, the clinical response to the
treatment at 8 weeks was 87% in patients who had not been
previously treated with an anti-TNF agent and 67% in
those who had switched from another anti-TNF [76].
Another prospective study in 90 patients with CD or UC
found decreases in scores of disease activity after 6 weeks
of treatment with the biosimilar [81]. One of these obser-
vational cohort studies explored the use of CT-P13 in
pediatric patients with CD (n = 32) [82]. The results of
these studies should be interpreted with a degree of caution
based on the underlying limitations of the study designs.
3.6 Health Economics Evidence: Infliximab
Biosimilars
Studies of infliximab biosimilars are presented in Table 3.
CT-P13 (Remsima/Inflectra; Celltrion) Following the
launch of CT-P13 in several major European countries,
health economic studies have emerged evaluating the
budget impact and cost effectiveness (from a payer or
patient perspective) of introducing the biosimilar into the
chronic inflammatory disease market [84, 85, 86, 87,
88, 83, 89]. Published studies to date have explored the
potential cost savings realized from substituting the origi-
nator with CT-P13 for the treatment of CD, UC, RA, AS,
and PsA across multiple European countries. The totality of
evidence from these studies points towards substantial cost
savings, with the degree of budget impact dependent on the
rate of interchangeability, patient number, and eligibility of
treatment with the biosimilar (i.e., whether patients are
treatment-naı¨ve or treatment-experienced), along with the
acquisition cost of the biosimilar. These authors have
attempted to quantitatively demonstrate that the introduc-
tion of a biosimilar may provide additional budget to treat
more patients (including, for example, those with earlier-
stage disease) on an annual basis, which could potentially
alleviate both the short- and longer-term cost burden
among healthcare payers and providers.
3.7 Preclinical and Clinical Data on Intended
Copies
3.7.1 Intended Copies of Etanercept
Studies of etanercept intended copies are presented in
Table 5.
Infinitam (Probiomed) One preliminary safety/efficacy
RCT for Infinitam in patients with moderate to severe RA
(n = 58) was identified [124]. The results suggested similar
efficacy, safety, and pharmacokinetic/pharmacodynamic
outcomes between Infinitam and etanercept at 24 weeks.
An observational study investigating Infinitam, Yisaipu
(etanercept intended copy), or Kikuzubam (rituximab
intended copy) in patients with rheumatic diseases reported
that a large proportion of patients experienced AEs, with
more than one-third of AEs reportedly occurring on the
same day as first treatment [125].
Yisaipu (Shanghai CP Guojian Pharmaceutical Co.)
An observational retrospective cohort study was performed
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in 158 patients with active RA treated with Yisaipu
(etanercept intended copy) (n = 62), adalimumab
(n = 61), or infliximab (n = 35) [126]. Similar decreases
in Disease Activity Score in 28 joints (DAS28) were seen
at 24 months. No statistically significant differences were
seen in the number of patients achieving remission. The
authors noted that fewer AEs were present in the Yisaipu
treatment group than in the adalimumab- and infliximab-
treated patients. Only one health economics study was
identified for etanercept biosimilars/intended copies [127].
This study assessed the cost effectiveness of reduced doses
or discontinuation of Yisaipu in patients with moderately
active RA. Strategies starting with Yisaipu 50 mg/week
for 9 months followed by Yisaipu 25 or 50 mg/week
maintenance showed the greatest number of quality-ad-
justed life-years (QALYs) gained. The incremental cost-
Table 5 Outcomes for etanercept intended copies









[moderate and severe RA
(58)]
CA [124] Efficacy, week 24: Modified D&B:
excellent; score:
9/12
DAS28 (score) 2.8 2.4
Safety Similar Similar
PK/PD NR NR p = 0.355
Observational [rheumatic
diseases (219)]













Observational [RA (802)] CA [48] NA Modified D&B: good;
score: 5/12






11.2 ADA: 13.1; IFX: 8.5 NS
DAS28 low score,
week 104 (%)
16.1 ADA: 11.4; IFX: 17.1 NS
DAS28 moderate
score, BL (%)
51.6 ADA: 45.9; IFX: 34.2 NS
DAS28 moderate
score, week 104 (%)
9.6 ADA: 11.4; IFX: 14.2 NS
DAS28 high score,
BL (%)
9.6 ADA: 8.2; IFX: 28.5 NS
DAS28 high score,
week 104 (%)















ADA adalimumab, AE adverse event, BL baseline, CA conference abstract, D&B Downs and Black (tool), DAS28 Disease Activity Score in 28
joints, ICER incremental cost-effectiveness ratio, IFX infliximab, LY life-year, MTX methotrexate, NA not available, NR not reported, NS non-
significant, PD pharmacodynamic, PK pharmacokinetic, QALY quality-adjusted life-year, RA rheumatoid arthritis, RCT randomized controlled
trial
a Qualitative data for biosimilarity as stated by the corresponding study authors
b Nine strategies evaluated. Most cost-effective strategy is shown
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Table 6 Outcomes for rituximab intended copies










Efficacy, week 24: Modified D&B:
good; score: 5/12DAS-CRP NR NA p\ 0.0001
DAS-ESR NR NA p\ 0.0001
ACR20 (%) 97 NA
Safety, week 24:
All SAEs (n) 0
Observational/ prospective




CA [130] Safety: Modified D&B: fair;
score: 4/12All AEs (%) 14.3 NA
Chills (%) 20 NA
Headache (%) 16.7 NA
Fever (%) 13.0 NA




Mild AEs (%) 90.0 NA
Moderate AEs (%) 6.7 NA
Severe AEs (%) 3.3 NA
Mortality (%) 0 NA
Observational/prospective
[biologic-naı¨ve RA (21)]
[131] Efficacy: D&B: good; score:




DAS28 LDA (year 1) (%) 33 NA
DAS28 LDA (year 3) (%) 43 NA
DAS28 remission (year 1)
(%)
57 NA




Serious AEs (n) 0 NA
Infusion reactions (%) 10 NA
Nonclinical (cell-based) [132] Functional assessment
(in vitro):
Not evaluatedb
ADCC (%) 80–125 80–125 NS
CDC (3 batches) (%) 81; 111; 108 NR







[132] Composition: Not evaluatedb
Peptide mapping Same Same




DSC analysis Similar Similar
Cation exchange, acid (%) 7.0 22.1
Cation exchange, main (%) 20.6 68.5
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effectiveness ratio (ICER) was most sensitive to the
acquisition cost of Yisaipu.
3.7.2 Intended Copies of Rituximab
Studies of rituximab intended copies are presented in
Table 6.
Kikuzubam (Probiomed) The biochemical characteri-
zation and in vitro biological activity of Kikuzubam (and
RedituxTM) versus rituximab have been assessed in a pre-
clinical study [132]. Study findings provided evidence of
similar potency to rituximab. As previously mentioned, an
observational study investigating Kikuzubam (or Infini-
tam/Yisaipu) in patients with rheumatic diseases
reported that a large proportion of patients experienced
AEs [125].
RedituxTM (Dr Reddy’s Laboratories) RedituxTM has
been evaluated in two independent nonclinical studies,
wherein the drug was reported to exhibit similar biological
effects in vitro to rituximab (in cell-based assays)
[132, 133]. Two nonclinical studies examined structural
attributes of RedituxTM and reported heterogeneity
between it and rituximab with respect to theoretical mass
and secondary/tertiary structure [132, 135, 134]. Three
observational trials were identified that assessed clinical
outcomes for RedituxTM [130, 128, 129, 131]. Although
none of these studies provided a comparator, there is some
evidence supporting the efficacy and safety of RedituxTM
Table 6 continued




Analytical CA [134] Composition: Not evaluatedb





Analytical CA [135] Composition: Not evaluatedb
SDS-PAGE Similar Similar
iCE NR NR Significant
CE NR NR Significant
CEX-HPLC NR NR Significant
Kikuzubam
Nonclinical (cell-based) [132] Functional assessment
(in vitro):
Not evaluatedb
ADCC (%) 80–125 80–125 NS





[132] Composition: Not evaluatedb
Peptide mapping Same Same




DSC analysis Similar Similar
Cation exchange, acid (%) 37.8 22.1/7.0
Cation exchange, main (%) 56.6 68.5/20.6







ACR20 American College of Rheumatology 20% improvement criteria, ADAb anti-drug antibodies, ADCC antibody-dependent cell-mediated cytotoxicity,
AE adverse event, BL baseline, CA conference abstract, CDC complement-dependent cytotoxicity, CE capillary electrophoresis, CEX-HPLC cation-
exchange chromatography high-performance liquid chromatography, CRP C-reactive protein, D&B Downs and Black (tool), DAS Disease Activity Score,
DAS28 Disease Activity Score in 28 joints, DMARD disease-modifying antirheumatic drug, DSC differential scanning calorimetry, ESR erythrocyte
sedimentation rate, iCE imaged capillary electrophoresis isoelectric focusing, IdeS Immunoglobulin-degrading enzyme from Streptococcus pyogenes,
LDA low disease activity, NA not available, NR not reported, PPS per protocol set, RA rheumatoid arthritis, SDS-PAGE sodium dodecyl sulfate
polyacrylamide gel electrophoresis
a Qualitative data for biosimilarity as stated by the corresponding study authors
b Quality assessment not conducted due to the absence of validated tools specific for the study type, at the time of analysis
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in the treatment of chronic inflammatory disease and, in
particular, for treatment of RA.
3.8 Quality Assessment of the Studies
The quality of all included randomized and non-random-
ized studies were assessed using validated instruments.
3.8.1 National Institute for Health and Care Excellence
(NICE) Single Technology Appraisal (STA)
Manufacturer’s Template
Seven RCTs were assessed using the NICE STA manu-
facturer’s template [42, 44, 49, 33, 101, 69, 59] (Tables 1,
2, 3, ESM Fig. S3a); all were considered excellent quality
overall. The RCTs provided information to assess the
randomization process, subject withdrawals, outcome
selection, reporting bias, and statistical analyses, which
were adequately reported in all studies. The bias of allo-
cation concealment process was unclear in three studies
(Jani et al. [33], Yi et al. [44], and Yoo et al. [69]). The
blinding process was unclear in one study (Yoo et al. [69])
and assessed as high risk for unblinding in one study (Gu
et al. [42]).
3.8.2 Jadad Scoring Tool
Seven RCTs were evaluated using the Jadad scoring tool
(Tables 1, 2, 3, ESM Fig. S3b). Choe et al. [101] and
Emery et al. [49] scored high for reporting on the five
scored regions of randomization, blinding, methodology,
withdrawals, and dropouts (total score 5 points). Gu et al.
[42] reported an open-label study and, therefore, scored the
maximum possible 3 points [42]; Jani et al. [33] and Park
et al. [59] both failed to report on the method of blinding,
and therefore scored 4 points each; Yi et al. [44] and Yoo
et al. [69] failed to report on both the randomization and
blinding methods, thereby scoring 3 points each.
3.8.3 Downs and Black/Modified Downs and Black
Instrument
Four observational studies with full-study reporting were
assessed using the Downs and Black scoring tool (Tables 3
and 6, ESM Fig. S4) [80, 76, 78, 131]; all were considered
fair quality. The restrictive word count in abstracts from
conference proceedings generally provide limited infor-
mation on study methodologies and outcomes. For this
reason, the Downs and Black instrument was adapted to
assess the quality of the 22 identified abstracts for addi-
tional original studies (Tables 1, 2, 3, 4, 5, 6, ESM Fig. S5)
[26, 41, 47, 48, 98, 63, 46, 119, 122,
103, 81, 74, 79, 82, 124, 125, 126, 130, 128, 104, 50, 34].
The average score for the abstract publications was 7.8 out
of a possible 12 points. The total score was fair quality
(3–4) for four studies [81, 74, 125, 130], good quality (5–8)
for seven studies [48, 122, 79, 82, 126, 128, 104], and
excellent quality (9–12) for 11 studies [26, 41, 47, 98, 63,
45, 119, 103, 124, 50, 34]. The majority of the studies
published as conference abstracts were of good or excellent
quality (81.8%).
3.8.4 Drummond’s Checklist
Three pharmacoeconomic studies were assessed using
Drummond’s checklist for assessing economic evaluations
(Tables 3 and 5, ESM Fig. S6) [84, 87, 127]; the studies
were of good quality. Of a maximum 36 points, Brodszky
et al. [84] scored 23 points, Jha et al. [87] scored 23 points,
and Wu et al. [127] scored 29 points.
3.8.5 SYRCLE’s Risk of Bias Tool
Three animal studies were assessed using SYRCLE’s risk
of bias tool (Tables 2, 4, ESM Fig. S7) [52, 115, 108]. The
three studies were of moderate quality.
3.9 Weight and Breadth of Evidence
for Biosimilarity
The final determination of biosimilarity by regulatory
authorities (e.g., the FDA [136]) is based on the ‘totality of
evidence’ approach and the degree of residual uncertainty
concerning biosimilarity between the proposed biosimilar
and the innovator drug. The authorities base their decision
on data from the molecular and functional characterization,
any nonclinical data obtained, and the safety, pharma-
cokinetic, immunogenicity, and efficacy clinical trial data
provided by the manufacturer. However, given that regu-
latory submissions are not publically available and the full
dataset therein cannot be systematically reviewed, the
authors have instead based all analysis in this literature
review on information from the peer-reviewed literature.
All comparative publications uncovered in this literature
review were carefully assessed to analyze the reported
extent of similarity between the originator product and the
biosimilar. Biosimilarity (based on combined evidence
from all related published studies) for each type of study
was graded as comparable, highly similar, similar, or non-
similar, which was directly inferred from investigator
conclusions (Table 7). The available comparative data
from full-text publications of randomized clinical trials are
currently limited. However, based on original investigator
conclusions from the literature at the time the search was
undertaken, the current data from clinical, nonclinical, and
observational/post-marketing studies for proposed
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biosimilars indicate moderate to high levels of biosimi-
larity to the comparator products (Table 7).
In order to summarize findings, the total number of
studied variables and total reported patient numbers were
extracted from the identified analytical/nonclinical and
clinical studies, respectively. These parameters were then
mapped (Fig. 2a, b) against the ‘degree of similarity’ (as
observed by the study investigator) in an effort to depict the





















Adalimumab ABP 501 (Amgen, USA) 4 or 44 44 44 NA NA
GP2017 (Sandoz, Switzerland) NA 44 NA NA NA
PF-06410293 (Pfizer, USA) 44 44 NA NA NA
SB5 (Samsung Bioepis, South
Korea)
NA NA 44 NA NA
ZRC-3197 (ExemptiaTM; Cadila
Healthcare, India)
NA NA NA 44 NA
Etanercept AVG01 (AventTM; Avesthagen,
India)




NA NA 44 NA NA




NA NA 44 44 NA
LBEC0101 (LG Life Sciences,
South Korea)
NA NA 44 NA NA
SB4 (Benepali; Samsung
Bioepis, South Korea)
NA NA 44 44 NA
Infliximab BOW015 (Infimab; Ranbaxy
Laboratories, India/Epirus
Biopharmaceuticals, USA)




44 or 444 44 44 44 a
PF-06438179 (Pfizer, USA) 44 or 444 44 44 NA NA
SB2 (Flixabi; Samsung Bioepis,
South Korea)
NA NA 44 44 NA
Rituximab CT-P10 (Celltrion, South Korea/
Hospira, USA)
NA NA 44 NA NA
GP2013 (Sandoz, Switzerland) 444 4 NA NA NA
PF-05280586 (Pfizer, USA) 44 or 444 44 44 NA NA
RTXM83 (mAbxience,
Switzerland)
4 4 NA NA NA
Intended copies Infinitam (Probiomed, Mexico) NA NA 44 NA a
Yisaipu (Etanar; Shanghai CP
Guojian Pharmaceutical, China)
NA NA NA NA a
RedituxTM (Dr Reddy’s
Laboratories, India)
6 or 44 4 NA NA a
Kikuzubam (Probiomed,
Mexico)
6 or 444 44 NA NA a
NA not applicable, evidence from published studies not available, PK pharmacokinetic, SAE serious adverse events, 444 identical (based on
combined evidence from all related published studies),44 highly similar (based on combined evidence from all related published studies),4 similar
(based on combined evidence from all related published studies), 6 non-similar (based on combined evidence from all related published studies)
a Not possible to draw conclusions from published studies, due to the lack of direct comparative data with the originator
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Fig. 2 Biosimilarity and a total treated patients for named biosim-
ilars and intended copies in published clinical trials and b breadth of
data for named biosimilars and intended copies in published
analytical and nonclinical studies. ‘Degree of similarity’ for biosim-
ilars and intended copies is inferred from the totality of evidence
provided from all available published studies (up to 3 September
2015), and is based on the original conclusions made by the study
investigators. The scale of reference used by each investigator was not
accounted for, as it was not uniformly reported. * refers to agents that
have already met the European Medicines Agency and/or US Food
and Drug Administration requirements and have been approved as
biosimilars.  based on different author interpretations of study data,
intended copy Kikuzubam purportedly exhibits some highly
dissimilar and some identical physicochemical characteristics com-
pared with the originator. ADA adalimumab, ETN etanercept, IC
intended copy, INF infliximab, RTX rituximab
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overall quantity of available evidence for each agent. Most
biosimilars have published clinical data on fewer than 100
human subjects, whereas studies of CT-P13 have involved
more than 1000 subjects (Fig. 2a). Studies of 13 biosimi-
lars identified included 4522 patients or healthy subjects.
Approved biosimilars CT-P13 (infliximab biosimilar
Remsima/Inflectra), SB2 (infliximab biosimilar, Flix-
abi), and SB4 (etanercept biosimilar, Benepali) reported
the largest combined study populations from pharmacoki-
netic/safety, comparative efficacy/safety, and observational
studies (1405, 743, and 734 patients, respectively). Four
intended copies were identified in studies including a total
of 1430 patients.
When considering the breadth of data available for
preclinical studies (based on the number of variables
studied in structural, functional, and nonclinical studies)
for named biosimilars, there is an inconsistent amount of
reported information available across studies (Fig. 2b). PF-
05280586 (rituximab) and GP2013 (rituximab) were found
to have a larger number of investigated variables for ana-
lytical and nonclinical biosimilarity. Of note, Flores-Ortiz
et al. [132] reported that the mass spectrometry and cation
exchange findings were heterogeneous for the intended
copy Kikuzubam in comparison to its rituximab origina-
tor, while other variables (differential scanning calorimetry
analysis, peptide mapping, glycan quantification, etc.) were
reported to be the same. Thus, the positioning on the x axis
(Fig. 2b) was determined to be both dissimilar and iden-
tical across selected variables.
Although the original study investigators concluded that
the majority of agents exhibited biosimilarity to their
originator, it is worth noting that comparative data were not
provided for all attributes studied.
3.10 Non-Empirical Publications
A summary of information from the non-empirical publi-
cations is shown in ESM Table S5. Within the 34 identified
empirical publications, 16 were therapy area overviews (in
RA, AS, UC/CD, and dermatology) and 11 articles dis-
cussed regulatory policy. Other topics included biosimilar
development, national guidelines, safety/pharmacovigi-
lance, and substitution/interchangeability. One theme that
was discussed in many of the articles (at least 17 of the 34
publications) was the extrapolation of clinical data from
clinical trials of biosimilars between different indications.
In many of the 17 publications, the extrapolation of clinical
trial data of the biosimilar infliximab CT-P13 (Remsima/
Inflectra) from RA patients to patients with UC/CD was
discussed in detail due to the fact that CT-P13 was origi-
nally approved by the EMA, but not the Canadian
authorities, for the treatment of UC/CD. Whilst the EMA
considered that ‘‘high similarity’’ in preclinical studies
together with clinical data from two trials in AS and RA
warrant the ‘‘extrapolation’’ for CD and UC, Canadian
authorities did not initially accept extrapolation, based on
differences in glycosylation (fucosylation) in irrita-
ble bowel syndrome. However, CT-P13 has now been
approved by Health Canada for additional indications,
including CD and UC.
3.11 Additional Planned and Ongoing Trials
of Adalimumab, Etanercept, Infliximab,
and Rituximab Biosimilars
The ClinicalTrials.gov registry was consulted to identify
planned or ongoing trials not yet reported in the published
literature. Trials were listed for biosimilars for adalimumab
in a total of 14 studies (ESM Table S6). The clinical trials
search also identified biosimilars of adalimumab not yet
appearing in the published literature. Biosimilars produced
by Coherus Biosciences, Inc. (USA), LG Life Sciences
(South Korea), Boehringer Ingelheim (Germany), and
Biocad (Russia) were identified for adalimumab (CHS-
1420, LBAL, BI 695501, and BCD-057, respectively).
A total of nine studies were listed in the ClinicalTri-
als.gov database for named biosimilars of etanercept (ESM
Table S6). Trials were also identified for a newly identified
biosimilar, CHS-0214 (Coherus Biosciences, Inc.; two
studies co-sponsored with Daiichi Sankyo Co. Ltd. and one
with Baxalta US Inc.).
A total of three clinical trials were retrieved from the
search for named biosimilars of infliximab in ClinicalTri-
als.gov (ESM Table S6). An additional biosimilar, BCD-
055 (Biocad), was identified from this search, which was
not identified in the published literature search.
Seven trials were identified in the ClinicalTrials.gov
search for named biosimilars of rituximab for the treatment
of RA only (ESM Table S6). One biosimilar (BI 695500)
that had not been reported in the published literature was
identified from this search.
Although the majority of patient studies listed for
development candidates of adalimumab, etanercept, and
infliximab were in RA (for ABP 501 [adalimumab],
BI 695501 [adalimumab], PF-06410293 [adalimumab],
SB5 [adalimumab], CHS-0214 [etanercept], ENIA11
[etanercept], LCEC0101 [etanercept], and PF-06438179
[infliximab]), several complete or ongoing studies were
also identified for psoriasis or plaque psoriasis for
ABP 501, CHS-1420 (adalimumab), GP2017 (adali-
mumab), CHS-0214, and GP2015 (etanercept). In addition,
for infliximab biosimilars BCD-055 and CT-P13, studies
were recruiting in AS and CD, respectively, at the time of
analysis.
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3.12 Key Journals and Congresses
A total of 98 journals publishing relevant material on
biosimilars for chronic inflammatory disease were iden-
tified during this review (ESM Table S7). Annals of the
Rheumatic Diseases published the greatest number of
articles on this topic during the search period (ten articles
since 2013). Prior to 2011, no journal articles relevant to
the topic of MAb or fusion protein biosimilars were
published that were relevant to chronic inflammatory
diseases and there has been a steady rise since then (two,
six, ten, and 14 articles in 2011, 2012, 2013, and 2014,
respectively). In the last complete year of the analysis
(2014), the European Journal of Health Economics pub-
lished the greatest number of articles related to biosimi-
lars in chronic inflammatory disease (four articles),
followed by Annals of the Rheumatic Diseases (three
articles), and the Journal of Crohn’s and Colitis (three
articles).
A total of 28 congresses were identified that presented
abstracts of named biosimilars relevant to chronic inflam-
matory diseases between January 2010 and August 2015
(ESM Table S8). No congress abstracts were identified in
the years preceding 2010. A total of 54 abstracts were
published in the year 2014 for these congresses. Of these,
the largest number of abstracts were published for dis-
semination at European League Against Rheumatism
(EULAR) (17 abstracts), ACR (13 abstracts), and Inter-
national Society For Pharmacoeconomics and Outcomes
Research (ISPOR) (ten abstracts) congress meetings. The
sharp increase in the number of abstract publications from
2013 to 2014 at these congresses (30 to 54 abstracts)
highlights the high level of interest in biosimilars for the
treatment of chronic inflammatory diseases among clinical,
regulatory, and payer stakeholders. The search also cap-
tured abstracts published between January and August
2015. A total of 22 abstracts were presented at EULAR and
11 at European Crohn’s and Colitis Organisation (ECCO)
congress meetings.
4 Discussion
Guidelines require that biosimilars should exhibit close
similarity to the originator with respect to structure (pri-
mary and higher-order) and many other molecular char-
acteristics, display similar levels of biological potency
in vitro or in vivo, and should meet the required thresholds
for bioequivalence in safety and pharmacokinetic studies
before entering a comparative trial(s) in patients to satisfy
efficacy requirements [2]. Robust evidence of similarity
provided from analytical, pharmacokinetic, and nonclinical
studies is thus equally as important as clinical evidence to
demonstrate the safety and efficacy of a biosimilar, and to
meet regulatory standards and requirements set by the
EMA and FDA for approval [137, 138]. While these data
are generated as evidence for approval, ensuring the data
are made available in the public domain is also important
for promoting education and awareness and encouraging
acceptance of biosimilars among physicians and other
healthcare professionals.
At the time of data analysis, the totality of evidence for
candidate biosimilars with comparative studies in chronic
inflammatory disease suggested that the majority of
biosimilars demonstrated a moderate to high degree of
similarity to their originator. In contrast, there was limited
information in the public domain regarding the similarity
of intended copies with their originator products.
This SLR revealed several biosimilar molecules that met
the required standards. CT-P13 (Remsima/Inflectra) is
the only commercially available infliximab biosimilar to
date that has been launched across 12 European countries
and Canada, and approved in the USA. The combined
evidence gathered from analytical, nonclinical, and clinical
studies (identified in this review of publications to
3 September 2015) supported the premise that CT-P13 is
safe and effective [63, 91, 90, 66, 121, 67, 72, 69, 71,
64, 139, 92, 73, 70, 68]. A comparative safety/efficacy
study is underway in CD and CT-P13 is also being eval-
uated in observational studies for multiple other chronic
inflammatory conditions (including ankylosing spondy-
loarthritis, PsA, UC, CD, and chronic psoriasis) [63, 59,
58, 61, 123, 62, 80, 81, 76, 77, 78, 74, 79, 75, 82, 64,
68, 65, 60]. PF-06438179 is another infliximab biosimilar
that has exhibited moderate to high structural and func-
tional similarity during analytical and preclinical investi-
gations [94, 95, 93, 98, 99, 97, 96]. At the time of this
review, a comparative safety/efficacy trial comparing the
efficacy and immunogenicity of PF-06538179 versus
infliximab was recruiting patients with RA. Adalimumab
biosimilars GP2017 and PF-06410293 both showed simi-
larity to adalimumab in in vitro assays and preclinical
studies [37, 36, 35, 38, 39]. At the time of analysis, pro-
gression of PF-06410293 into three pharmacokinetic/safety
studies and one comparative safety/efficacy trial had been
listed on ClinicalTrials.gov and comparative safety/effi-
cacy trials for GP2017 were underway in the treatment of
plaque psoriasis. For GP2015, an etanercept biosimilar,
published nonclinical (in vitro and in vivo) data revealed
close functional similarity compared with its originator
[53]. Finally, rituximab biosimilars GP2013 and PF-
05280586 both showed adequate degrees of similarity to
rituximab during preclinical phases of development
[117, 115, 116]. Some pharmacokinetic/safety trials and
preliminary safety/efficacy trials for RA have also been
reported [114, 109, 111, 113, 108, 112, 104, 106, 107, 105].
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For the prescribing physician and key decision-makers,
it is important to understand whether the published data on
biosimilarity are of sufficient quality to influence pre-
scribing decisions. Therefore, as well as investigating the
weight of available data, this review also used validated
instruments, such as the NICE STA assessment, Jadad
scoring tool, Downs and Black checklist, Drummond
scoring system for economic studies, and SYRCLE’s risk
of bias tool for animal studies to assess the quality of
studies. The results were reassuring; of the seven RCTs
assessed, all were considered to be of excellent quality by
the NICE STA assessment, and all scored between 3 and
5 points using the Jadad scoring tool.
Taken together, the weight and breadth of evidence of
comparative studies suggest that biosimilars will soon
become a mainstay of treatment in many different chronic
inflammatory diseases. The non-empirical publication
analysis in this report suggests that the reduced cost of
biosimilars and the increased number of available thera-
peutic options may make access to biologic therapy
available to a broader subset of patients. This is particularly
important for chronic diseases such as RA, AS, UC, and
CD where patients need treatment with costly biologic
therapy for long periods of time [6]. Indeed, it has often
been shown in these diseases that early aggressive therapy
has long-term benefits both for the prevention of joint
deterioration (in the case of RA) [140] and quality of life
[141, 142]. The availability of relatively low-cost biosim-
ilars may eventually alter the treatment paradigm so that
patients are treated for less time with conventional disease-
modifying antirheumatic drugs alone, and biologic therapy
is initiated earlier in the disease course [143].
Although the number and quality of published studies
providing evidence of structural and functional similarity at
the preclinical phase may not be sufficient to predict
behaviors or performance in humans, these studies form the
basis for demonstration of similarity and represent a crucial
step in the development program. At the time of analysis,
BOW015 (Infimab; infliximab; Ranbaxy Laboratories,
India/Epirus Biopharmaceuticals), CT-P10 (infliximab;
Celltrion), SB2 (Flixabi; infliximab; Samsung Bioepis);
SB5 (adalimumab, Samsung Bioepis), and ZRC-3197
(ExemptiaTM; adalimumab; Cadila Healthcare) had all
entered into clinical stages of development (comparative
safety/efficacy in RA) without published data or evidence
to suggest that they had similar structural or functional
resemblance to their originators. This was also true for the
majority of etanercept biosimilars (HD203 [DavictrelTM;
Hanwha Chemical], LBEC0101 [LG Life Sciences],
ENIA11 [TuNEX; Biotech/TSH Biopharm Corp., Tai-
wan], and SB4 [Benepali; Samsung Bioepis]), which had
all reported comparative safety/efficacy trials in RA with a
lack of published analytical or nonclinical data. Although
publication of similarity information is not a regulatory
requirement for the approval of biosimilars, a lack of
information in the public domain will impact on education
and awareness and therefore the ability of clinicians to
make informed prescribing decisions.
This review also provides information on marketed
intended copies (copies of originator biologics that have
not undergone rigorous comparative evaluations). Several
intended copies are commercially available with very little
evidence of biosimilarity. For example, intended copy
Kikuzubam (Probiomed) gained approval in Mexico
without published comparative safety/efficacy trials and
prior to COFEPRIS releasing official regulatory guidance
on ‘biocomparables’ [17]. In 2012, Kikuzubam was
withdrawn by the regulatory authority due to documented
anaphylactic reactions and a lack of clinical data [144].
Intended copy RedituxTM (Dr Reddy’s Laboratories) was
also commercialized in Latin American countries, India,
and Iran without published data to indicate structural or
functional similarity or clinical effectiveness as compared
with rituximab [145]. Although several observational
studies have been reported for RedituxTM, no studies for
chronic inflammatory conditions included rituximab as a
comparator at the time of this review
[132, 133, 135, 134, 130, 128, 129, 131]. Intended copy
Yisaipu (etanercept; Shanghai CP Guojian Pharmaceuti-
cal Co.) is a fusion protein that is already marketed in
China. However, as is evident from this review, no pub-
lished data are available for comparison with etanercept to
determine its biosimilarity. In Colombia, Yisaipu is
marketed under the brand name Etanar. At the time of this
review, only one limited clinical trial (not an equivalence
study comparing Yisaipu with etanercept) had been
reported [48, 126, 127]. Finally, at the time that this
analysis was completed, there was only one study that
assessed the efficacy and safety of intended copy Infini-
tam, which is currently marketed in Mexico [124]. Suffice
to say, significant data gaps remain for intended copies,
reinforcing the need to maintain a clear differentiation
between these molecules and true biosimilars.
Non-empirical data analysis suggests that some coun-
tries are only just beginning to establish formal regulatory
guidelines for the approval of biosimilars to cover
requirements for preclinical, clinical, or other analyses that
should be used to demonstrate the safety, quality, and
effectiveness of a biosimilar. This includes studies required
for immunogenicity and AEs, as well as demonstration of
similar modes of action or pharmacodynamic properties to
that of the originator. Other countries have yet to imple-
ment any guidelines. The extrapolation of biosimilarity
information across indications was also an issue that was
mentioned frequently in the non-empirical publications
identified in this report [144, 146, 147,
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148, 149, 150, 151, 152, 153,
154, 155, 156, 157, 158, 159, 160]. A common theme of
discussion was the fact that RA (where almost all mole-
cules were first investigated) may not be a sensitive clinical
model to detect potential differences between biosimilars
and originator products that may be observed in UC/CD. It
was suggested that the immunogenicity potential of
biosimilars is fairly low in RA and even further suppressed
by the concomitant use of methotrexate, and that regulatory
agencies should grant extrapolated indications to biosimi-
lars based on appropriate scientific justification only after
biosimilarity is confirmed [152, 154].
This systematic review aims to provide a comprehensive
summary of literature relevant to mAb and fusion protein
biosimilars for the treatment of chronic inflammatory dis-
eases. However, there are some inherent weaknesses and
limitations to this method of data analysis. As with any
systematic review, the search retrieved records citing a
particular term (either a mAb or fusion protein biosimilar).
Due to a lack of consensus on the naming of biosimilars
and intended copies, no consistent nomenclature could be
relied upon to identify and correctly classify every possible
molecule of interest. Molecules may, for example, have
been incorrectly termed biosimilars in the literature without
rigorous data to support biosimilarity to the originator
product. The authors’ determination of biosimilarity for
each molecule was limited to using only the specific terms
(e.g., ‘‘similar’’ or ‘‘highly similar’’) reported by the
investigators. Consequently, the analysis is based purely on
the scale of reference used by the original investigators.
In addition, only data from studies disclosing names of
biosimilars or intended copies (i.e., utilizing a unique
identifier) and from journals or abstracts published in
English were extracted. Clinical trial information was
taken from the ClinicalTrials.gov database; no other clin-
ical trial registries were consulted in this analysis. It is
therefore possible that information on some regional trials
may not have been captured.
One of the original aims of our research was to identify
gaps in the published literature. With this in mind, the
results presented contain only the outcomes data and sta-
tistical comparisons available from the published abstracts
or full-text articles retrieved from the search. Thus, the
information collated may not be representative of the full
extent of data available for each study, only that which has
been published. It should be noted that the search strategy
was designed to capture only articles published by
MEDLINE- or EMBASE-indexed journals. Therefore,
studies published by non-indexed journals were not inclu-
ded. A full Internet search of all online content was not
included in the methodology.
It should also be noted that proceedings from only 17
conferences were searched, and thus additional data may be
available from other conference proceedings not consid-
ered in this analysis. Furthermore, at the time of analysis,
only limited outcomes data were available from published
conference abstracts, with no full-text publications avail-
able at the time of the review.
Lastly, the authors also acknowledge that the delay
between regulatory submission and publication of studies
may partially explain why there is limited information
available for those biosimilars that are newly approved.
A number of biosimilars have newly published data
and new molecules (which were not included in this
review) may now also be in development for the treat-
ment of chronic inflammatory diseases. For example, at
the time of writing, comparative safety/efficacy trials
were listed in the ClinicalTrials.gov registry for M923
(adalimumab; Baxalta) for the treatment of chronic pla-
que-type psoriasis and moderate to severe RA, and for
MYL-1401A (adalimumab; Mylan) in patients with pso-
riasis and PsA. In addition, other studies of biosimilars
included in the review have since been listed in the
ClinicalTrials.gov registry. For the infliximab biosimilar
CT-P13 (Remsima/Inflectra), two observational studies
(one in RA and one in AS) and one post-marketing study
(in RA patients [PERSIST]) have been listed. BCD-055
(infliximab biosimilar) has comparative safety/efficacy
trials planned in AS and RA. Three new studies for
adalimumab biosimilars have also been added. A multi-
center clinical study to evaluate the usability and safety of
a pre-filled pen and pre-filled syringe in RA is reportedly
complete (SB5), GP2017 has a comparative safety/effi-
cacy RA trial listed (ADMYRA), and there is a com-
parative safety/efficacy trial planned for BCD-057 in the
treatment of plaque psoriasis (CALYPSO). For etanercept
biosimilars, GP2015 is being studied (EQUIRA) and
LBEC0101 is under evaluation for the treatment of RA.
The rituximab biosimilar BCD-020 is being investigated
with methotrexate as first-line biologic therapy for
patients with active RA (ALTERRA). The number of new
biosimilars and clinical trials identified illustrates the
speed at which this field of medicine is progressing. This
is a highly competitive market, as illustrated by Epirus
Biopharmaceuticals suspending development of the
biosimilar BOW015 (Infimab; infliximab) in May 2016,
citing the evolving biosimilar competitive and business
landscape as the primary reason [161].
As discussed here, there is a need to recognize and
maintain a clear distinction between biosimilars and
intended copies. However, since it is not always apparent
from publicly available sources what manufacturers’
intentions are, the term ‘proposed biosimilars’ is employed
in this analysis as a blanket term for all development
candidates pending final determination of their status as
biosimilars.
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There are examples of molecules that are currently
marketed as biosimilars in countries outside of the EU or
USA: HD203 (DavictrelTM; Hanwha Chemical) was
approved by the Korean MFDS in 2014 [162] and BOW-
015 (Infimab; infliximab; development now suspended)
and ZRC-3197 (ExemptiaTM; adalimumab) were also
approved in India [145]. As noted by Castan˜eda-Herna´ndez
et al. [145], it is not yet known whether other countries will
approve these products as biosimilars based on the data
currently available.
5 Conclusions
This SLR sought to collate and synthesize publicly avail-
able information on biosimilars on the market and in
development for chronic inflammatory disease to support
healthcare decision-making. As anticipated, at the time of
this review, all approved biosimilars had published data
providing evidence of biosimilarity from RCT studies. At
the analysis cut-off, only CT-P13 had additional published
evidence from analytical and nonclinical studies.
A number of proposed biosimilars are also amassing a
significant body of evidence from studies across devel-
opment stages. The majority of agents were found to
exhibit a high degree of similarity to their originators,
based on investigator conclusions. However, the authors
found that significant gaps in the evidence base for some
pipeline products remain, and this is also true for all of
the intended copies identified. As shown in this review,
only one intended copy had published RCT data and this
was from a preliminary safety/efficacy study. The impli-
cations of these intended copies being marketed without a
transparent evidence base are multi-fold and the authors
advise caution in the use of these molecules. Apart from
the obvious safety issues, this lack of transparency may
have a broad impact on adoption of biosimilars in general
and cause confusion among healthcare stakeholders.
While the authors acknowledge that the existence of data
not yet published may potentially address these gaps, if it
is not in the public domain it will do little to alleviate
these concerns.
RA is the first market in which multiple biosimilars have
been launched and, undoubtedly, experience in this market
will influence how the broader sector evolves. Therefore,
the ongoing dissemination of data by all manufacturers is
imperative to instill confidence and support adoption of
biosimilars in healthcare practice.
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